Decera Clinical Education Oncology Podcast
Science

Decera Clinical Education Oncology Podcast

by Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

101 episodes
EN language
All Episodes
1
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer
33:23 Mar 19, 2026
2
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer
22:22 Mar 13, 2026
3
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
30:24 Mar 11, 2026
4
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
37:14 Mar 9, 2026
5
Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
16:44 Mar 9, 2026
6
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
38:32 Feb 27, 2026
7
Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer
22:26 Feb 23, 2026
8
Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer
47:50 Feb 20, 2026
9
Individualized Hemophilia Care With Hemostatic Rebalancing Therapies
29:19 Jan 30, 2026
10
Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET
31:02 Jan 21, 2026
11
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
17:30 Dec 30, 2025
12
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
14:59 Dec 30, 2025
13
Expert Highlights From the 2025 World Conference on Lung Cancer
24:30 Dec 24, 2025
14
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
15:45 Dec 23, 2025
15
PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
14:25 Dec 19, 2025
16
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
17:39 Dec 18, 2025
17
PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
22:20 Dec 17, 2025
18
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
20:37 Nov 18, 2025
19
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
22:14 Nov 6, 2025
20
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
26:01 Nov 5, 2025
21
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
35:16 Oct 31, 2025
22
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
27:48 Oct 28, 2025
23
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
26:10 Oct 14, 2025
24
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer
23:57 Oct 14, 2025
25
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options
37:10 Oct 13, 2025
26
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma
22:53 Sep 11, 2025
27
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
13:57 Sep 4, 2025
28
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma
16:48 Sep 3, 2025
29
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
20:20 Aug 26, 2025
30
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
29:59 Aug 15, 2025
31
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
24:49 Aug 12, 2025
32
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
39:12 Jul 28, 2025
33
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
35:02 Jul 25, 2025
34
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
18:04 Jul 25, 2025
35
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
22:23 Jul 24, 2025
36
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
21:24 Jul 23, 2025
37
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
31:19 Jul 18, 2025
38
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
35:36 Jul 18, 2025
39
Experts Discuss CELMoDs in Myeloma
35:51 Jul 15, 2025
40
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
35:15 May 29, 2025
41
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
21:54 May 16, 2025
42
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies
29:36 May 5, 2025
43
How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities
16:41 Apr 25, 2025
44
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
18:34 Apr 24, 2025
45
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies
14:09 Apr 21, 2025
46
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
14:42 Mar 25, 2025
47
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer
45:08 Feb 20, 2025
48
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
20:01 Feb 10, 2025
49
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
36:04 Jan 9, 2025
50
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
20:40 Oct 22, 2024
Select an episode
0:00 0:00